Novel Pharmacotherapies for Alzheimer's Disease
Journal of the Korean Medical Association
; : 1059-1068, 2009.
Article
em Ko
| WPRIM
| ID: wpr-29405
Biblioteca responsável:
WPRO
ABSTRACT
Alzheimer disease (AD) is pathologically characterized by extracellular amyloid deposits composed of beta-amyloid (A beta) peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and deficit of cholinergic neurons in the basal forebrain. It is the most common neurodegenerative disease in the elderly. With the aging of the population, the incidence and prevalence of AD will also increase rapidly. The subsequent growing socioeconomic burden seems to be inevitable until effective therapeutic strategies are developed. Currently available treatments approved by the US Food and Drug Administration, while ameliorating the symptoms, do not halt progression or cure the illness. AD is a multifactorial syndrome with several target proteins contributing to its etiology. In this review, various small molecules targeting pathological hall marks or their major constituents that have been reported in the literature will be discussed, with emphasis on compounds that are presently being investigated in clinical trials.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
United States Food and Drug Administration
/
Envelhecimento
/
Proteínas
/
Incidência
/
Prevalência
/
Prosencéfalo
/
Emaranhados Neurofibrilares
/
Placa Amiloide
/
Doenças Neurodegenerativas
/
Neurônios Colinérgicos
Tipo de estudo:
Incidence_studies
/
Prevalence_studies
/
Prognostic_studies
Limite:
Aged
/
Humans
Idioma:
Ko
Revista:
Journal of the Korean Medical Association
Ano de publicação:
2009
Tipo de documento:
Article